| __timestamp | Apellis Pharmaceuticals, Inc. | Celldex Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 2908166 | 20622000 |
| Thursday, January 1, 2015 | 6356782 | 33837000 |
| Friday, January 1, 2016 | 4303743 | 35979000 |
| Sunday, January 1, 2017 | 10463151 | 25003000 |
| Monday, January 1, 2018 | 22639184 | 19269000 |
| Tuesday, January 1, 2019 | 67046483 | 15426000 |
| Wednesday, January 1, 2020 | 139401000 | 14456000 |
| Friday, January 1, 2021 | 176771000 | 20488000 |
| Saturday, January 1, 2022 | 277163000 | 27195000 |
| Sunday, January 1, 2023 | 500815000 | 30914000 |
Unveiling the hidden dimensions of data
In the competitive world of biotechnology, managing costs is crucial for success. This chart compares the Selling, General, and Administrative (SG&A) expenses of Apellis Pharmaceuticals, Inc. and Celldex Therapeutics, Inc. from 2014 to 2023. Over this period, Apellis Pharmaceuticals has seen a staggering increase in SG&A expenses, growing by over 17,000% from 2014 to 2023. In contrast, Celldex Therapeutics has maintained a more stable trajectory, with expenses fluctuating modestly around a 50% increase over the same period.
This divergence highlights the different strategic paths these companies have taken. Apellis's aggressive expansion is evident in its rising costs, while Celldex's steadier approach reflects a more conservative growth strategy. Understanding these trends provides valuable insights into the operational strategies of these biotech firms, offering a glimpse into their future potential.
Comparing SG&A Expenses: Johnson & Johnson vs Apellis Pharmaceuticals, Inc. Trends and Insights
Who Optimizes SG&A Costs Better? AbbVie Inc. or Celldex Therapeutics, Inc.
Breaking Down SG&A Expenses: Novartis AG vs Apellis Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Catalent, Inc. or Apellis Pharmaceuticals, Inc.
Walgreens Boots Alliance, Inc. vs Celldex Therapeutics, Inc.: SG&A Expense Trends
Comparing SG&A Expenses: Axsome Therapeutics, Inc. vs Celldex Therapeutics, Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for ADMA Biologics, Inc. and Apellis Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Apellis Pharmaceuticals, Inc. or Viking Therapeutics, Inc.
Apellis Pharmaceuticals, Inc. and Arrowhead Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Apellis Pharmaceuticals, Inc. and Mesoblast Limited
Apellis Pharmaceuticals, Inc. or Travere Therapeutics, Inc.: Who Manages SG&A Costs Better?
Comparing SG&A Expenses: Celldex Therapeutics, Inc. vs Xencor, Inc. Trends and Insights